RxDoctor Payments Data

Russell Snook, MD

Ophthalmology · Lewisville, TXNPI 1225046238

Payments from drug & device makers

$2,920in general payments, 2019–2025

Across 110 payments — averaging $26.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$665
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$429
  • Johnson & Johnson Surgical Vision, Inc.$415
  • Bausch & Lomb Americas Inc.$407
  • Rxsight Inc$335
  • Ocular Therapeutix, Inc.$183
  • plus $487 from 9 others

What the payments were for

  • Food & beverage$2,920100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,920 in reported general payments places this provider in the 55th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$448,578
Medicare patients
1,630
Services billed
3,511

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$62,059
LumiganBimatoprost60$39,612
MieboPerfluorohexyloctane/Pf39$36,064
BesivanceBesifloxacin Hcl101$21,612
Cyclosporine33$17,086
ProlensaBromfenac Sodium41$13,975
Latanoprost902$11,189
RhopressaNetarsudil Mesylate21$8,592
Prednisolone Acetate284$7,725
CombiganBrimonidine Tartrate/Timolol12$6,680
SimbrinzaBrinzolamide/Brimonidine Tart16$5,983
Bromfenac Sodium32$5,431
VyzultaLatanoprostene Bunod17$4,730
Brinzolamide14$4,652
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$3,808

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$665$108,351121 claims
Bausch & Lomb Americas Inc.Miebo, Vyzulta$407$40,79456 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa, Loteprednol Etabonate$429$37,066163 claims
AlconSimbrinza$124$5,98316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Lewisville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →